论文部分内容阅读
目的观察及评价紫杉醇与多西紫杉醇加5-氟尿嘧啶、顺铂方案对晚期胃癌的近期疗效及其无进展生存期(PFS)、毒副反应。方法选取2013年1月至2015年1月收治的晚期胃癌90例,按随机数表法分为紫杉醇组(n=45)与多西紫杉醇组(n=45)。紫杉醇组方案为紫杉醇+5-氟尿嘧啶+顺铂;多西紫杉醇组方案为多西紫杉醇+5-氟尿嘧啶+顺铂。均于化疗4个周期后观察两种方案对胃癌患者进行一线化疗的效果及不良反应。结果紫杉醇组的治疗总有效率为64.4%,多西紫杉醇组总有效率为57.8%,两组比较差异无统计学意义(P>0.05)。紫杉醇组的PFS为6.3个月,多西紫杉醇组PFS为6.7个月,两组比较差异无统计学意义(P>0.05)。在化疗不良反应方面,多西紫杉醇组骨髓抑制及液体潴留发生率均高于紫杉醇组(P均<0.01),而两组胃肠道反应、脱发、肝脏毒性发生率比较差异无统计学意义(P均>0.05)。结论紫杉醇+5-氟尿嘧啶+顺铂方案化疗与多西紫杉醇+5-氟尿嘧啶+顺铂方案治疗晚期胃癌的近期疗效相似,但多西紫杉醇组致骨髓抑制及液体潴留较紫杉醇组多见。
Objective To observe and evaluate the short-term efficacy, progression-free survival (PFS) and toxicity of paclitaxel plus docetaxel plus 5-fluorouracil and cisplatin in advanced gastric cancer. Methods Ninety patients with advanced gastric cancer who were admitted from January 2013 to January 2015 were divided into paclitaxel group (n = 45) and docetaxel group (n = 45) by random number table. Paclitaxel group plan paclitaxel + 5 - fluorouracil + cisplatin; docetaxel group plan for docetaxel + 5-fluorouracil + cisplatin. After 4 cycles of chemotherapy were observed two kinds of programs for gastric cancer patients first-line chemotherapy results and adverse reactions. Results The total effective rate of paclitaxel group was 64.4%, and the total effective rate of docetaxel group was 57.8%. There was no significant difference between the two groups (P> 0.05). PFS in paclitaxel group was 6.3 months, and PFS in docetaxel group was 6.7 months. There was no significant difference between the two groups (P> 0.05). In adverse reactions of chemotherapy, the incidence of bone marrow suppression and fluid retention in docetaxel group were higher than those in paclitaxel group (P <0.01), but there was no significant difference in the incidence of gastrointestinal reaction, alopecia and liver toxicity P> 0.05). Conclusions Paclitaxel + 5-fluorouracil plus cisplatin regimen has similar efficacy in the treatment of advanced gastric cancer with docetaxel + 5-fluorouracil plus cisplatin regimen. However, docetaxel has more bone marrow suppression and fluid retention than paclitaxel.